Physician profile
Melissa Lambert
NPI 1922287564
$47,264.87
in general payments reported to CMS, 2019-2025
36 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,472 · 2022: $3,299 · 2023: $8,234 · 2024: $14K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,294 · Travel and Lodging: $3,687 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,645 · Education: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,784.38 |
| Consulting Fee | $10,443.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,293.50 |
| Travel and Lodging | $3,686.69 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,645.00 |
| Education | $641.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $15,065.08 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $8,392.50 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Arcutis Biotherapeutics, INC. | $4,918.53 | 2023-2025 | Zoryve |
| Abbvie INC. | $2,400.75 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,758.25 | 2021-2025 | |
| Janssen Biotech, INC. | $1,750.61 | 2022-2025 | Tremfya |
| Genzyme Corporation | $1,651.96 | 2021-2025 | |
| Incyte Corporation | $1,175.95 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $1,145.17 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $1,142.92 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $1,039.16 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Ucb, INC. | $1,024.24 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $989.95 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Regeneron Healthcare Solutions, INC. | $869.73 | 2021-2025 | Dupixent |
| Pfizer INC. | $718.31 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $652.29 | 2022-2024 | Vtama |
| Amgen INC. | $564.46 | 2021-2025 | Otezla, Otezla |
| Mimedx Group, INC. | $425.60 | 2024-2025 | |
| Journey Medical Corporation | $375.43 | 2021-2025 | |
| Almirall LLC | $186.88 | 2021-2024 | Seysara |
| Janssen Scientific Affairs, LLC | $186.56 | 2024 | Tremfya |
| Organon LLC | $156.78 | 2023-2025 | Hadlima, Vtama |
| Vyne Pharmaceuticals INC. | $130.34 | 2021 | |
| Biofrontera INC. | $77.58 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.41 | 2023-2025 | Spevigo, Cyltezo |
| Paratek Pharmaceuticals, INC. | $59.12 | 2024-2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $58.70 | 2022-2025 | |
| Botanix Sb INC | $54.40 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $40.91 | 2024 | Ycanth |
| Epi Health, LLC | $35.42 | 2021-2022 | |
| Convatec INC. | $31.65 | 2025 | |
| Sanofi-Aventis U.S. LLC | $31.40 | 2021 | |
| Genentech USA, INC. | $26.95 | 2023 | Erivedge |
| Kyowa Kirin, INC. | $23.50 | 2024 | Poteligeo |
| Teva Pharmaceuticals USA, INC. | $13.21 | 2024 | Simlandi |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.